An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly develo** area …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

Develo** drugs that target KRAS, the most frequently mutated oncogene in cancer, has
not been successful despite much concerted efforts dedicated towards it in the last thirty …

It has been long recognized that cancer cells reprogram their metabolism under hypoxia
conditions due to a shift from oxidative phosphorylation (OXPHOS) to glycolysis in order to …

The nuclear factor erythroid 2-related factor 2 (NRF2)–Kelch-like ECH-associated protein 1
(KEAP1) regulatory pathway plays an essential role in protecting cells and tissues from …

Cancer therapies targeting epidermal growth factor receptor (EGFR), such as small-
molecule kinase inhibitors and monoclonal antibodies, have been developed as standard …

Simple Summary Our manuscript summarizes the up-to-date data on the complex and
dynamic nature of adaptation mechanisms and evolutionary processes taking place during …

The use of circulating tumor DNA (ctDNA) as a novel and non-invasive test for the diagnosis
and surveillance of cancer is a rapidly growing area of interest, with sequencing of ctDNA …

The creation of novel anticancer treatments for a variety of human illnesses, including
different malignancies and dangerous microbes, also potentially depends on nanoparticles …